Literature DB >> 7584882

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.

S Eriksson1, A Eriksson, R Stege, K Carlström.   

Abstract

Bone mineral density (BMD) and bone mineral content (BMC) were measured in the femoral neck area, trochanteric area and Wards triangle, and in the distal radius of the left forearm before and after 1 year of endocrine treatment in 27 patients with prostatic cancer. Eleven of the patients were treated with orchidectomy and 16 with combined oral and intramuscular estrogens. The patients were free from metastases during the entire observation period. In the orchidectomized patients, BMD and BMC of the distal radius decreased significantly following treatment, whereas no changes were observed in the estrogen-treated patients. These preliminary results demonstrate that estrogens may protect bone in male subjects also and may merit further investigations on larger groups of patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584882     DOI: 10.1007/BF00298427

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  16 in total

1.  Treatment of prostatic carcinoma with various types of estrogen derivatives.

Authors:  G Jönsson; A M Olsson; W Luttrop; Z Cekan; K Purvis; E Diczfalusy
Journal:  Vitam Horm       Date:  1975       Impact factor: 3.421

2.  Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.

Authors:  P Henriksson; M Blombäck; A Eriksson; R Stege; K Carlström
Journal:  Br J Urol       Date:  1990-03

Review 3.  Steroid hormones, ageing and bone.

Authors:  R G Crilly; R M Francis; B E Nordin
Journal:  Clin Endocrinol Metab       Date:  1981-03

4.  Adrenocortical steroids, bone mineral content and endometrial condition in post-menopausal women.

Authors:  S Brody; K Carlström; A Lagrelius; N O Lunell; L Rosenborg
Journal:  Maturitas       Date:  1982-08       Impact factor: 4.342

Review 5.  Treatment of prostate cancer with gonadotropin-releasing hormone agonists.

Authors:  F Labrie; A Dupont; A Bélanger; R St-Arnaud; M Giguère; Y Lacourcière; J Emond; G Monfette
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

6.  Orchidectomy or oestrogen treatment in prostatic cancer: effects on serum levels of adrenal androgens and related steroids.

Authors:  R Stege; A Eriksson; P Henriksson; K Carlström
Journal:  Int J Androl       Date:  1987-08

7.  Prognostic value of serum hormone concentrations in prostatic cancer.

Authors:  A Eriksson; K Carlström
Journal:  Prostate       Date:  1988       Impact factor: 4.104

8.  Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause.

Authors:  C L Hughes; L L Wall; W T Creasman
Journal:  Gynecol Oncol       Date:  1991-01       Impact factor: 5.482

9.  Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).

Authors:  D Goldray; Y Weisman; N Jaccard; C Merdler; J Chen; H Matzkin
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

10.  C19 adrenal steroids enhance prostaglandin F2 alpha output by human endometrium in vitro.

Authors:  L Markiewicz; E Gurpide
Journal:  Am J Obstet Gynecol       Date:  1988-08       Impact factor: 8.661

View more
  29 in total

Review 1.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  Sarcopenia during androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Fred Saad; Blair Egerdie; Paul R Sieber; Teuvo L J Tammela; Chunlei Ke; Benjamin Z Leder; Carsten Goessl
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 3.  Bone health and the female athlete triad in adolescent athletes.

Authors:  Kathryn E Ackerman; Madhusmita Misra
Journal:  Phys Sportsmed       Date:  2011-02       Impact factor: 2.241

Review 4.  Treatment-related osteoporosis in men with prostate cancer.

Authors:  Matthew R Smith
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 5.  Estrogen therapy in patients with prostate cancer: a contemporary systematic review.

Authors:  Leonardo Oliveira Reis; Emerson Luis Zani; Herney Andrés García-Perdomo
Journal:  Int Urol Nephrol       Date:  2018-03-29       Impact factor: 2.370

6.  Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.

Authors:  Alan I So; Kim N Chi; Brita Danielson; Neil E Fleshner; Anil Kapoor; Tamim Niazi; Frederic Pouliot; Ricardo A Rendon; Bobby Shayegan; Srikala Sridhar; Eric Vigneault; Fred Saad
Journal:  Can Urol Assoc J       Date:  2019-12-05       Impact factor: 1.862

7.  A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Authors:  Joshua M Lang; Marianne Wallace; Jordan T Becker; Jens C Eickhoff; Bjoern Buehring; Neil Binkley; Mary Jane Staab; George Wilding; Glenn Liu; Miroslav Malkovsky; Douglas G McNeel
Journal:  Clin Genitourin Cancer       Date:  2013-07-05       Impact factor: 2.872

Review 8.  Men, bone and estrogen: unresolved issues.

Authors:  E S Orwoll
Journal:  Osteoporos Int       Date:  2003-03-04       Impact factor: 4.507

Review 9.  Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Estrogenic side effects of androgen deprivation therapy.

Authors:  Theresa A Guise; Michael G Oefelein; James A Eastham; Michael S Cookson; Celestia S Higano; Matthew Raymond Smith
Journal:  Rev Urol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.